[Form 4] Virios Therapeutics, Inc. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

Dogwood Therapeutics, Inc. (DWTX) – Form 4 insider filing dated 07/01/2025

Director John C. Thomas reported the grant of 2,362 stock options on 06/27/2025 at an exercise price of $4.71 per share. The options become exercisable on 06/27/2026 and expire on 06/27/2035. Following this award, the director beneficially owns 2,362 derivative securities, held directly. No open-market purchases or sales of common stock were disclosed, and no indirect holdings were reported. The filing was signed by Attorney-in-Fact Greg Duncan.

Insights

Securities Analyst

TL;DR: Small routine option grant; minimal dilution or signaling impact.

This Form 4 reflects a standard equity incentive: 2,362 director stock options at $4.71, vesting after one year. Given the modest size, the grant is unlikely to move valuation or float materially. It does, however, align the director’s interests with shareholders through performance-linked compensation. No buying or selling of common shares occurred, so there is no bullish or bearish trading signal. Overall, this is routine governance housekeeping rather than a catalyst for the stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thomas John C

(Last) (First) (Middle)

C/O DOGWOOD THERAPEUTICS, INC.

44 MILTON AVENUE

(Street)

ALPHARETTA GA 30009

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.71	06/27/2025		A		2,362		06/27/2026	06/27/2035	Common Stock	2,362	$0	2,362	D

Explanation of Responses:

	/s/ Greg Duncan, Attorney-in-Fact	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for DWTX on 07/01/2025?

A director received 2,362 stock options at a $4.71 exercise price, no common shares were bought or sold.

When do the newly granted Dogwood Therapeutics options become exercisable?

The options vest and become exercisable on 06/27/2026.

What is the expiration date of the reported Dogwood Therapeutics stock options?

The options expire on 06/27/2035.

Did the filing show any open-market purchases or sales of Dogwood Therapeutics common stock?

No, the Form 4 disclosed only an option grant; there were no common-stock trades.

How many derivative securities does the director own after this transaction?

The director now beneficially owns 2,362 stock options.